Company news
Acrux Limited (ASX:ACR) news
Acrux Limited news releases on 6ix. Latest, Oct 1, 2026: Acrux has received $1.977m RDTI rebate for FY26
Press releases & updates
Acrux has received $1.977m RDTI rebate for FY26
October 1, 2026
FY26 Annual Report and Appendix 4E
August 25, 2026
Investor Presentation - Female Testosterone for HSDD
August 5, 2026
Update - Licensing Lenzetto for Australia for AUD5.4m
May 28, 2026
Acrux licenses Lenzetto for Australian market for AUD5.4m
May 27, 2026
Capital Gains Tax exemptions remain in place for Acrux
May 13, 2026
Acrux raises $1.6 million via Share Placement
May 11, 2026
Australian company unlocks a new era for women's health globally with an innovative delivery system for Female testosterone in women with low libido
April 28, 2026
Acrux strategy focuses on Female Testosterone for low libido
April 27, 2026
Acrux receives $0.55m advance on FY26 R&D Tax Incentive
March 11, 2026
Half Yearly Report and Accounts
February 24, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 28, 2026
Divestment of Prilocaine 2.5% and Lidocaine 2.5%, Cream
December 11, 2025
AGM Presentation and Address
November 24, 2025
Acrux receives $0.4m advance on FY26 R&D Tax Incentive
November 12, 2025
Received $3.04m RDTI rebate for FY25
September 3, 2025
Appendix 4E and Full Year Statutory Accounts FY25
August 28, 2025
Licensing partnership in Saudi Arabia for Dapsone 5%, Gel
July 30, 2025
Receipt of second advance for FY25 R&D Tax Incentive
July 2, 2025
Dapsone 7.5%, Gel launched in the United States
May 8, 2025
Acrux CEO and Managing Director appointment
May 6, 2025
Acrux receives $1.73m advance on FY25 R&D Tax Incentive
April 2, 2025
Investor Presentation February 2025
February 25, 2025
Appendix 4D and December 2024 Half Year Accounts
February 25, 2025
Acrux CEO announces plan to retire
February 6, 2025
Monthly Activities/Appendix 4C Cash Flow Report
January 29, 2025
Launch of 90 gram pack size of Dapsone 5%, Gel in US
January 15, 2025
Acrux raises $1.34 million from SPP
December 22, 2024
Investor Deck update, SPP Closes 18 December 2024, 5pm
December 17, 2024
Commercialisation of Nitroglycerin Ointment
December 12, 2024
Share Purchase Plan Offer Booklet
December 5, 2024
Investor Presentation
December 5, 2024
Share Placement successfully concluded and SPP launched
December 4, 2024
FDA Approval - Nitroglycerin Ointment
December 3, 2024
Trading Halt
December 2, 2024
AGM Presentation
November 20, 2024
FY24 R&D Tax Incentive rebate received
October 1, 2024
ASX Small and Mid Cap Conference presentation
September 23, 2024
FY24 Full Year Results - Investor Presentation
August 29, 2024
Appendix 4E and FY24 Full Year Statutory Accounts
August 29, 2024
FDA Approval received for Dapsone Gel, 7.5%
August 26, 2024
Quarterly Activities Report and Appendix 4C - June 2024
July 25, 2024
Acrux presentation to Bioshares, 18th Biotech Summit
July 14, 2024
RDTI funding facility secured
June 27, 2024
Acrux presentation at Hidden Gems in Lifesciences Forum
June 12, 2024
Launch of Dapsone 5%, Gel in the United States
April 2, 2024
Investor Presentation Half Year Accounts
February 27, 2024
Appendix 4D and Half Year Accounts
February 27, 2024
Appendix 4C and Activities Statement
January 30, 2024
Address of Chair and CEO to AGM
November 28, 2023